Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV

A prior T cell depletion induced by HIV infection may carry deleterious consequences in the current COVID‐19 pandemic. Clinical data on patients co‐infected with HIV and SARS‐CoV‐2 are still scarce.

[1]  C. Sabin,et al.  Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Wayne T. A. Enanoria,et al.  COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco , 2020, Journal of acquired immune deficiency syndromes.

[3]  P. Sax,et al.  Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Morris,et al.  Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Jessica K De Freitas,et al.  Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. V. von Herrath,et al.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[7]  R. López-Vélez,et al.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.

[8]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[9]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[10]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[11]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[12]  Meilin Liu,et al.  Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis , 2020, Journal of Infection.

[13]  J. Blanco,et al.  COVID-19 in patients with HIV – Authors' reply , 2020, The Lancet HIV.

[14]  A. Giacomelli,et al.  Clinical features and outcomes of HIV patients with coronavirus disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Aiping Le,et al.  T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 , 2020, The Journal of infectious diseases.

[16]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[17]  M. Bickel,et al.  COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients , 2020, Infection.

[18]  C. Giaquinto,et al.  How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review , 2020, Journal of Infection.

[19]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[20]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[21]  Denisa Bojkova,et al.  Lack of antiviral activity of darunavir against SARS-CoV-2 , 2020, International Journal of Infectious Diseases.

[22]  A. Elfiky,et al.  Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study , 2020, Life Sciences.

[23]  K. Liang,et al.  A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China , 2020 .

[24]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[25]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[26]  Jincun Zhao,et al.  T cell-mediated immune response to respiratory coronaviruses , 2014, Immunologic Research.

[27]  R. Medzhitov,et al.  Not so fast: adaptive suppression of innate immunity , 2007, Nature Medicine.

[28]  Hong Tang,et al.  Adaptive immune cells temper initial innate responses , 2007, Nature Medicine.